David Fox

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Health Insurance

Glycemic Control

Epstein Barr Virus

Diffuse Large B Cell Lymphoma

Top Venues

Advances in therapy

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Justin Gatwood, Anthony Masaquel, David Fox, Daniel Sheinson, Cameron James, Jia Li, Farah Hossain, Ryan Ross
Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-Cell lymphoma. Journal of medical economics (2024)
Justin Gatwood, Anthony Masaquel, David Fox, Daniel Sheinson, Cameron James, Jia Li, Farah Hossain, Ryan Ross
Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma. Journal of medical economics 27 (1) (2024)
Justin Gatwood, Anthony Masaquel, David Fox, Daniel Sheinson, Cameron James, Jia Li, Farah Hossain, Ryan Ross
Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma. Journal of medical economics 27 (1) (2024)
David Fox, Tu My To, Arpamas Seetasith, Anisha M Patel, Susan T Iannaccone
Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis. Advances in therapy 40 (3) (2022)
David Fox, Tu My To, Arpamas Seetasith, Anisha M Patel, Susan T Iannaccone
Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis. Advances in therapy 40 (3) (2022)
David Fox, Tu My To, Arpamas Seetasith, Anisha M Patel, Susan T Iannaccone
Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis. Advances in therapy (2022)
David Fox, Tu My To, Arpamas Seetasith, Anisha M Patel, Susan T Iannaccone
Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis. Advances in therapy 40 (3) (2022)
David Fox, Tu My To, Arpamas Seetasith, Anisha M Patel, Susan T Iannaccone
Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis. Advances in therapy 40 (3) (2022)